Kaposiform Hemangioendothelioma Clinical Trial
Official title:
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled Trial
Verified date | March 2024 |
Source | Children's Hospital of Fudan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | November 1, 2025 |
Est. primary completion date | November 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 18 Years |
Eligibility | Inclusion Criteria: - Participant clinically or pathologically diagnosed with KHE, TA or complicated superficial vascular anomolies involving lymphatic components. 1. The case is initial, with a relatively limited superficial lesion. 2. The participant has residual surface lesions after oral medication. - Participant with no use of other medication or surgical treatment - Participant with detailed medical records of the disease at the time of screening - Participant with signed and dated informed consent from the guardian(s) Exclusion Criteria: - Participants with Kasabach-Merritt Phenomenon, with platelets <50×10 9 /L. - Participants with general disease such as hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency. - Participants with other hematological diseases or solid tumor. - Participants allergic to sirolimus or dressing. |
Country | Name | City | State |
---|---|---|---|
China | Children's Hospital of Fudan University | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Fudan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effective rate | Achauer BM et al. made the four-level standard as follows. Grade I: tumor size and skin lesion color regression = 25%; grade II: tumor size and skin lesion color regression 25%-50%; grade III: tumor size and skin lesion color regression 50-75%; grade IV: tumor size and skin lesion color regression =75%. After 6 months of treatment, the pzrticipant will be evaluated. Grade I will be viewed as invalid. Grade II and grade III will be viewed as effective, and grade IV will be viewed as very effective. Those in grade ?, ? or ? will be calculated in effectiveness rate. | From admission to follow-up six months | |
Secondary | Changes of resistance coefficient | Measured by ultrosonic doppler flowmetery at follow-up | From admission to follow-up six months | |
Secondary | Incidence of adverse events | Adverse events will be reported according to Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0). Incidence of complications such as oral ulcers, abnormal liver enzymes, infections will be recorded. It is defined as occurring if individual subject has any of the above complications during the 6-month intervention | From admission to follow-up six months | |
Secondary | Platelet count | Platelet count is one of the major indicators of response to treatment. It is supposed to be greater than 100×10^9/L. | From admission to follow-up six months | |
Secondary | Changes of peak blood flow | Measured by ultrosonic doppler flowmetery at follow-up | From admission to follow-up six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04077515 -
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
|
Phase 4 | |
Recruiting |
NCT05351216 -
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
|
||
Completed |
NCT03188068 -
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
|
Phase 2 | |
Completed |
NCT04448873 -
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
|
Phase 4 | |
Completed |
NCT04775173 -
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
|
Phase 2 | |
Recruiting |
NCT03001180 -
Identification of Biomarkers for Patients With Vascular Anomalies
|